GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. - Wikidata - awgldk - TriplyDB

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

http://www.wikidata.org/entity/Q37694758

about

Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.Antisecretory Factor-mediated Inhibition of Cell Volume Dynamics Produces Anti-tumor Activity in Glioblastoma.MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.

P2860

Q43416240-3EFE42BF-BA2D-4E09-84EE-98CE9801E175 Q50066649-5924FE55-586B-4F16-9DF6-0F1646DE4F53 Q53136216-43B0A0AB-82D6-425F-9699-D0ED1FAE2FA2

P2860

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

http://www.wikidata.org/entity/Q37694758

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

GBM heterogeneity as a functio ...... receptor variant III activity.

@en

GBM heterogeneity as a functio ...... receptor variant III activity.

@nl

type

label

GBM heterogeneity as a functio ...... receptor variant III activity.

@en

GBM heterogeneity as a functio ...... receptor variant III activity.

@nl

prefLabel

GBM heterogeneity as a functio ...... receptor variant III activity.

@en

GBM heterogeneity as a functio ...... receptor variant III activity.

@nl

P1433

Q37694758-ADE2C9B4-9632-4CAB-A742-45D62254966B

P1476

Q37694758-6894BE04-E375-4935-AFD3-45BFEDB7ECE8

P2093

Q37694758-06E853FE-6133-491D-A09F-09ADDFAB513B

Q37694758-1187C389-5783-4BC0-9FA0-1635A0F6C4D9

Q37694758-16639E7C-6C7C-4AC8-AB7E-E863DDDF111C

Q37694758-4231408B-618B-4CFE-AFF0-33E689B13FB9

Q37694758-42BD0C53-AD41-40B0-A3AB-A91F529103C1

Q37694758-4C35573F-0AC6-484E-859F-577E5CAC5F11

Q37694758-868090B3-E121-41C5-BBF0-24AC456B5D5A

Q37694758-8B2422E1-AA22-496A-A99A-1BA467521964

Q37694758-B5053089-2C51-4977-80A3-6195934A9083

Q37694758-D87C60CE-E83F-4759-BEAB-078AC760CD2E

P2860

Q37694758-04336450-BD8C-4BD7-B73B-0A2728CB2FF6

Q37694758-0DC63FF7-4B89-4347-A76D-83243DBB8FD6

Q37694758-109323D9-1720-413E-BD49-932BC6B64A32

Q37694758-1158CE90-E94F-4675-9C57-6B6D0E495F88

Q37694758-16E9F5C6-C450-4DAB-8A15-F38DD0AB2B47

Q37694758-1786226D-28AC-4706-A031-0A0D14E07D70

Q37694758-1A2BCD8F-3C0E-4293-A5FA-EB28F6D5214F

Q37694758-297B902B-AAA3-43C0-A1AC-12BE917E7866

Q37694758-2EB3442B-5297-4182-826D-DEF1BF88AE35

Q37694758-343C7FBE-8155-479A-9153-FF3D29EE7496

P304

Q37694758-6E7F7542-A92A-4646-B414-A5E1D6BDEAC9

P31

Q37694758-E9E3E8E2-F285-4242-A299-81CD5812790D

P356

Q37694758-A3EA10C7-CAB9-4F9F-9567-8BCB9319FAC2

P407

Q37694758-06EC7438-557F-4276-8383-4B6C8627EEBB

P433

Q37694758-25091903-8242-4F4A-8FFD-365BE2B9337F

P478

Q37694758-CEF457CE-F820-4F2B-B3B6-0A06060F2D67

P50

Q37694758-2DCDA288-7B2C-49B5-AB6F-E0503E4934E2

Q37694758-F3DF1815-20BF-4AE2-8292-EEE89DC0D6DA

P577

Q37694758-F7936815-5F4C-4AAA-906E-54A9812564C4

P698

Q37694758-CE4EF189-43C7-4DB0-95C1-60CD353DC42E

P932

Q37694758-60C242E1-8841-432B-B374-BA23065955C3

P356

ONCOTARGET.12600

P1433

P1476

GBM heterogeneity as a functio ...... receptor variant III activity.

@en

P2093

Aaron E Robinson

http://www.w3.org/2001/XMLSchema#string

Andrew J Ewald

http://www.w3.org/2001/XMLSchema#string

Andrew McKinney

http://www.w3.org/2001/XMLSchema#string

Annette M Molinaro

http://www.w3.org/2001/XMLSchema#string

C David James

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Huillard

http://www.w3.org/2001/XMLSchema#string

Gayane Koshkakaryan

http://www.w3.org/2001/XMLSchema#string

Jane R Engler

http://www.w3.org/2001/XMLSchema#string

Joanna J Phillips

http://www.w3.org/2001/XMLSchema#string

Joseph T Shieh

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The natural history of EGFR and EGFRvIII in glioblastoma patients

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells

Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

P304

79101-79116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12600

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Olle R Lindberg

P577

2016-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27738329

http://www.w3.org/2001/XMLSchema#string

P932

5346701

http://www.w3.org/2001/XMLSchema#string